Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04057573 · ClinicalTrials.gov registry record · Phase 3
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT04057573 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 344 participants.
The verdict
NCT04057573, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Interventions
- DRUG Vehicle
- DRUG Ruxolitinib cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2019-10-03 |
| Est. Completion | 2021-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04057573
The ClinicalTrials.gov registry entry for NCT04057573 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT04057573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04057573 about?
NCT04057573 is a clinical study titled "Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)". The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
What is the current status of trial NCT04057573?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2019-10-03. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04057573?
The interventions under investigation include: Vehicle (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT04057573?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.